Stock Research for SGYP


Featured Broker: Ally Invest

Get the due diligence for another stock.


SGYP Stock Chart & Research Data

The SGYP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SGYP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


SGYP Due diligence Resources & Stock Charts

The SGYP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SGYP Detailed Price Forecast - CNN Money CNN View SGYP Detailed Summary - Google Finance
Yahoo View SGYP Detailed Summary - Yahoo! Finance Zacks View SGYP Stock Research & Analysis -

Stock Analysis

TradeIdeas View SGYP Trends & Analysis - Trade-Ideas Barrons View SGYP Major Holders - Barrons
NASDAQ View SGYP Call Transcripts - NASDAQ Seeking View SGYP Breaking News & Analysis - Seeking Alpha
Spotlight View SGYP Annual Report - OTC Report View SGYP OTC Short Report -
TradeKing View SGYP Fundamentals - TradeKing Charts View SGYP SEC Filings - Bar Chart
WSJ View Historical Prices for SGYP - The WSJ Morningstar View Performance/Total Return for SGYP - Morningstar
MarketWatch View the Analyst Estimates for SGYP - MarketWatch CNBC View the Earnings History for SGYP - CNBC
StockMarketWatch View the SGYP Earnings - StockMarketWatch MacroAxis View SGYP Buy or Sell Recommendations - MacroAxis
Bullish View the SGYP Bullish Patterns - American Bulls Short Pains View SGYP Short Pain Metrics -

Social Media Mentions

StockTwits View SGYP Stock Mentions - StockTwits PennyStocks View SGYP Stock Mentions - PennyStockTweets
Twitter View SGYP Stock Mentions - Twitter Invest Hub View SGYP Investment Forum News - Investor Hub
Yahoo View SGYP Stock Mentions - Yahoo! Message Board Seeking Alpha View SGYP Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for SGYP - Insider Cow View Insider Transactions for SGYP - Insider Cow
CNBC View SGYP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SGYP - OTC Markets
Yahoo View Insider Transactions for SGYP - Yahoo! Finance NASDAQ View Institutional Holdings for SGYP - NASDAQ

Stock Charts

FinViz View SGYP Stock Insight & Charts - StockCharts View SGYP Investment Charts -
BarChart View SGYP Stock Overview & Charts - BarChart Trading View View SGYP User Generated Charts - Trading View

Latest Financial News for SGYP

CORRECTING and REPLACING Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business Update
Posted on Tuesday August 07, 2018

NEW YORK-- -- TRULANCE® second quarter net sales up over 40% versus prior quarter TRULANCE added to Express Scripts 2019 National Preferred Formulary List Synergy secures ex-US licensing deal for TRULANCE in China - providing $12 million upfront payment and potential for future milestone and escalating royalty payments In the "Ensuring a Strong Financial Foundation" section, first sentence ...

Synergy Pharmaceuticals (SGYP) Reports Q2 Loss, Tops Revenue Estimates
Posted on Tuesday August 07, 2018

Synergy Pharma (SGYP) delivered earnings and revenue surprises of 29.41% and 20.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

Synergy Pharma: 2Q Earnings Snapshot
Posted on Tuesday August 07, 2018

The New York-based company said it had a loss of 12 cents per share. The biopharmaceutical company posted revenue of $12.3 million in the period. In the final minutes of trading on Tuesday, the company's ...

Synergy Pharmaceuticals Announces TRULANCE® (plecanatide) Added to Express Scripts 2019 National Preferred Formulary List
Posted on Tuesday August 07, 2018

Synergy Pharmaceuticals Inc. (SGYP) today announced that leading U.S. pharmacy benefit manager, Express Scripts, will add TRULANCE to its National Preferred Formulary List, effective January 1, 2019. This follows the FDA approval of the second indication for TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) in January 2018. TRULANCE was first approved by the FDA for the treatment of adults with chronic idiopathic constipation (CIC) in January 2017.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.